SCHEDULE 13G: ARK Investment Management and Catherine Wood Disclose 5.2% Stake in Adaptive Biotechnologies

ARK Investment Management LLC and its CEO, Catherine D. Wood, have jointly disclosed a beneficial ownership of 5.2% in Adaptive Biotechnologies Corporation, totaling 7,732,570 shares of common stock.

Summary

• ARK Investment Management LLC and Catherine D. Wood have filed a Schedule 13G, reporting beneficial ownership of 7,732,570 shares of Common Stock in Adaptive Biotechnologies Corporation.
• This ownership represents 5.2% of the issuer's class of securities.
• The filing indicates that ARK Investment Management LLC holds sole voting and dispositive power over all 7,732,570 shares.
• Catherine D. Wood holds shared voting and dispositive power over the same 7,732,570 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• A client of ARK Investment Management LLC, specifically ARK Genomic Revolution ETF, has an interest in these securities exceeding 5 percent.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, indicating a neutral sentiment as it does not contain performance data, strategic updates, or forward-looking statements that would typically influence sentiment.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G filing is a standard regulatory disclosure by an institutional investor, ARK Investment Management LLC, and its principal, Catherine D. Wood, indicating a passive ownership stake exceeding 5% in a publicly traded company. Such filings provide transparency into significant equity holdings by large investment firms, which can sometimes signal institutional confidence or strategic positioning within a sector, though in this case, it explicitly states a passive investment intent.

Related Party Transactions

• ARK Investment Management LLC and Catherine D. Wood have entered into a joint filing agreement for this Schedule 13G.
• ARK Genomic Revolution ETF, a series of a Delaware statutory trust and a client of ARK Investment Management LLC, is known to have an interest in the reported securities exceeding 5 percent.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional holding, which can be viewed as a vote of confidence by a prominent investment firm, though the filing explicitly states a passive investment intent.
• Management: Awareness of a significant passive institutional investor on the shareholder register.

Key Dates

Keywords

Adaptive Biotechnologies Corporation, ARK Investment Management LLC, Catherine D. Wood, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Equity Stake